Short Interest in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Drops By 24.5%

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) was the recipient of a large decrease in short interest in the month of February. As of February 15th, there was short interest totalling 97,800 shares, a decrease of 24.5% from the January 31st total of 129,600 shares. Approximately 4.2% of the shares of the company are short sold. Based on an average trading volume of 774,100 shares, the short-interest ratio is presently 0.1 days.

ZyVersa Therapeutics Price Performance

ZyVersa Therapeutics stock opened at $1.06 on Wednesday. ZyVersa Therapeutics has a twelve month low of $0.98 and a twelve month high of $10.80. The firm has a 50 day moving average price of $1.26 and a 200-day moving average price of $1.70.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in ZyVersa Therapeutics stock. Virtu Financial LLC purchased a new stake in shares of ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 25,259 shares of the company’s stock, valued at approximately $27,000. Virtu Financial LLC owned approximately 1.08% of ZyVersa Therapeutics at the end of the most recent quarter. 3.91% of the stock is currently owned by hedge funds and other institutional investors.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.